Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).

In addition, we announced our second lead pipeline program for the treatment of acromegaly with clinical development expected to initiate in the second half of 2025. Our strong pipeline progress ...